Form 4: Carisma Therapeutics CEO Steven Kelly Granted Stock Options

Carisma Therapeutics' CEO, Steven Kelly, was granted stock options to purchase 125,000 shares of common stock on June 17, 2024.

Summary

• Steven Kelly, the President and CEO of Carisma Therapeutics Inc., was granted stock options on June 17, 2024.
• These options allow him to purchase 125,000 shares of Carisma Therapeutics' common stock at an exercise price of $1.03 per share.
• The options vest over two years, with 50% vesting on June 17, 2025, and the remaining 50% vesting on June 17, 2026, contingent upon continued service to the company.
• The options expire on June 17, 2034.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of stock options is a standard practice and generally viewed favorably as it aligns management's interests with shareholders. The vesting schedule promotes long-term commitment.

Positives

• The granting of stock options to the CEO aligns his interests with those of the shareholders, incentivizing him to improve the company's performance.
• The vesting schedule encourages long-term commitment from the CEO.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Juno Therapeutics (acquired by Celgene) and Kite Pharma (acquired by Gilead) also utilized stock options extensively to incentivize their leadership teams.
• The vesting schedule of two years is fairly typical, aligning with industry norms for executive retention.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the CEO to increase shareholder value.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates